1 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease– meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016; 64: 73–84.
2 Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 722–8.
3 Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated meta- bolic factors of nonalcoholic fatty liver disease in the general popula- tion from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 2012; 47: 586–95.
4 Milosevic I, Vujovic A, Barac A et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int. J. Mol. Sci. 2019; 20: 395.
5 Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in non- alcoholic fatty liver disease. Children. 2017; 4: 66.
6 Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T et al. The association of gut microbiota with nonalcoholic steatohepatitis in Thais. Biomed. Res. Int. 2018; 2018: 9340316.
7 Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 2017; 16: 375–81.
8 Tsai MC, Liu YY, Lin CC et al. Gut microbiota dysbiosis in patients with biopsy-proven nonalcoholic fatty liver disease: a cross-sectional study in Taiwan. Nutrients. 2020; 12: 820.
9 Ringel Y, Maharshak N, Ringel-Kulka T, Wolber EA, Sartor RB, Carroll IM. High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individ- uals. Gut Microbes. 2015; 6: 173–81.
10 Arase S, Watanabe Y, Setoyama H, Nagaoka N, Kawai M, Matsumoto S. Disturbance in the mucosa-associated commensal bac- teria is associated with the exacerbation of chronic colitis by repeated psychological stress; is that the new target of probiotics? PLoS One. 2016; 11: e0160736.
11 Libertucci J, Dutta U, Kaur S et al. Inflammation-related differences in mucosa-associated microbiota and intestinal barrier function in colonic Crohn’s disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2018; 315: G420–31.
12 Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and manage- ment of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018; 67: 328–57.
13 European Association for the Study of the Liver (EASL), European Asso- ciation for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guide- lines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388–402.
14 Schmieder R, Edwards R. Quality control and preprocessing of meta- genomic datasets. Bioinformatics. 2011; 27: 863–4.
15 Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010; 26: 2460–1.
16 DeSantis TZ, Hugenholtz P, Larsen N et al. Greengenes, a chimera- checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 2006; 72: 5069–72.
17 Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013; 57: 601–9.
18 Boursier J, Mueller O, Barret M et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the meta- bolic function of the gut microbiota. Hepatology. 2016; 63: 764–75.
19 Michail S, Lin M, Frey MR et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol. Ecol. 2015; 91: 1–9.
20 Kashiwagi S, Naito Y, Inoue R et al. Mucosa-associated microbiota in the gastrointestinal tract of healthy Japanese subjects. Digestion. 2020; 101: 107–20.
21 Nishino K, Nishida A, Inoue R et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. J. Gastroenterol. 2018; 53: 95–106.
22 Gevers D, Kugathasan S, Denson LA et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014; 15: 382–92.
23 Matsumoto H, Shiotani A, Katsumata R et al. Mucosa-associated micro- biota in patients with irritable bowel syndrome: a comparison of subtypes. Digestion. 2021; 102: 49–56.
24 Sugitani Y, Inoue R, Inatomi O et al. Mucosa-associated gut microbiome in Japanese patients with functional constipation. J. Clin. Biochem. Nutr. 2021; 68: 187–92.
25 Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012; 7: e39743.
26 Kitahata S, Yamamoto Y, Yoshida O et al. Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary bili- ary cholangitis. Sci. Rep. 2021; 11: 19705.
27 Van Herreweghen F, De Paepe K, Roume H, Kerckhof FM, Van de Wiele T. Mucin degradation niche as a driver of microbiome composi- tion and Akkermansia muciniphila abundance in a dynamic gut model is donor independent. FEMS Microbiol. Ecol. 2018; 94: fiy186.
28 Mantis NJ, Forbes SJ. Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol. Invest. 2010; 39: 383–406.
29 Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthésy B. Secretory component: a new role in secretory IgA- mediated immune exclusion in vivo. Immunity. 2002; 17: 107–15.
30 Bunker JJ, Bendelac A. IgA responses to microbiota. Immunity. 2018; 49: 211–24.
31 McCormick DA, Horton LWL, Mee AS. Mucin depletion in inflam- matory bowel disease. J. Clin. Pathol. 1990; 43: 143–6.
32 Palm NW, Zoete MR, Cullen TW et al. Immunoglobulin a coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014; 158: 1000–10.
33 Yi L, Xunyi Y, Lixiang L et al. Increased ileal immunoglobulin a production and immunoglobulin a-coated bacteria in diarrhea- predominant irritable bowel syndrome. Clin. Transl. Gastroenterol. 2020; 11: e00146.
34 Zhuang YP, Zhang YT, Zhang RX, Zhong HJ, He XX. The gut- liver axis in nonalcoholic fatty liver disease: association of intesti- nal permeability with disease severity and treatment outcomes. Int. J. Clin. Pract. 2022; 2022: 1–7.
論文の公開元へ
